Publications by authors named "Jing-Li Wu"
Background: Plasmodium falciparum apical membrane antigen-1 (PfAMA-1) is a promising candidate antigen for a blood-stage malaria vaccine. However, antigenic variation and diversity of PfAMA-1 are still major problems to design a universal malaria vaccine based on this antigen, especially against domain I (DI). Detail understanding of the PfAMA-1 gene polymorphism can provide useful information on this potential vaccine component.
View Article and Find Full Text PDF[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhonghua Gan Zang Bing Za Zhi
August 2009
Objective: To identify factors associated with response to lamivudine in chronic hepatitis B patients.
Methods: Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective. HBV DNA level and serum HBV markers were detected by polymerase chain reaction and enzyme-linked immunosorbent assay.
Objective: To investigate the association of serological markers of hepatitis B virus (HBV) and alanine transaminase (ALT) with hepatic tissue pathology in patients with chronic hepatitis B.
Methods: The serological marker of HBV, liver function and liver biopsy of 133 patients with chronic hepatitis B were measured and evaluated. The patients were divided into 4 groups according to HBeAg and HBV DNA positivity.
[A long-term observation and follow-up for patients with HBeAg/Anti-HBe seroconversion after lamivudine treatment].
Zhonghua Gan Zang Bing Za Zhi
April 2005
Objective: To observe the resulting change in patients who achieved HBeAg/Anti-HBe seroconversion after lamivudine treatment.
Methods: 68 patients were observed for over 24 months. They were HBeAg/Anti-HBe with a seroconversion time > or = 6 months and the course of lamivudine treatment was > or = 18 months.